Jun Lu | Cancer | Editorial Board Member

Published on by Oncology

Prof. Jun Lu | Cancer | Editorial Board Member

Professor | Chengdu University of Traditional Chinese Medicine | China

Dr. Jun Lu is a distinguished researcher at Chengdu University of Traditional Chinese Medicine, China, specializing in cancer nanomedicine, biomaterials, and translational therapeutics. His work focuses on the design and development of multifunctional nanoplatforms, including engineered chitosan nanoparticles, aptamer-conjugated chemotherapeutics, and self-gelling biomaterials for applications in tumor therapy, wound healing, and infectious disease management. Dr. Lu integrates molecular biology, materials science, and bioengineering to advance innovative therapeutic strategies, such as modulating tumor microenvironments, orchestrating DNA damage pathways in colorectal carcinoma, and promoting MRSA-infected wound healing. He has authored 78 publications in high-impact journals including Journal of Translational Medicine, Chemical Engineering Journal, Carbohydrate Polymers, and Nano Research, reflecting strong expertise in nanobiotechnology and translational oncology. His extensive collaborations with over 380 co-authors worldwide demonstrate his leadership in multidisciplinary research networks, bridging fundamental science with clinical applications. Beyond academic contributions, Dr. Lu’s work has significant societal impact by enabling advanced therapies for cancer, infectious diseases, and tissue repair, providing novel solutions to global health challenges. His research emphasizes translational relevance and real-world applicability, contributing to safer, more effective, and innovative therapeutic modalities. Dr. Lu’s academic influence and research productivity are reflected in his metrics 2,421 citations, 78 documents, and an h-index of 24.

Profiles: Google Scholar | Scopus | ORCID 

Featured Publications

Lu, J., Zhang, H., Hou, J., Li, X., Hu, X., Hu, Y., Easton, C. D., Li, Q., Sun, C., … (2020). Efficient metal ion sieving in rectifying subnanochannels enabled by metal–organic frameworks. Nature Materials, 19(7), 767–774. Cited by: 495

Ni, S., Yao, H., Wang, L., Lu, J., Jiang, F., Lu, A., Zhang, G. (2017). Chemical modifications of nucleic acid aptamers for therapeutic purposes. International Journal of Molecular Sciences, 18(8), 1683. Cited by: 384

Lu, J., Jiang, F., Lu, A., Zhang, G. (2016). Linkers having a crucial role in antibody–drug conjugates. International Journal of Molecular Sciences, 17(4), 561. Cited by: 352

Tan, C. M., Therien, A. G., Lu, J., Lee, S. H., Caron, A., Gill, C. J., Lebeau-Jacob, C., … (2012). Restoring Methicillin-Resistant Staphylococcus aureus susceptibility to β-lactam antibiotics. Science Translational Medicine, 4(126), 126ra35.
Cited by: 328

Li, F., Lu, J., Liu, J., Liang, C., Wang, M., Wang, L., Li, D., Yao, H., Zhang, Q., Wen, J., … (2017). A water-soluble nucleolin aptamer-paclitaxel conjugate for tumor-specific targeting in ovarian cancer. Nature Communications, 8(1), 1390.
Cited by: 275

 

Farhad Vahid | Breast Cancer | Editorial Board Member

Published on by Oncology

Dr. Farhad Vahid | Breast Cancer | Editorial Board Member

Assistance Professor | Luxembourg Institute of Health | Luxembourg

Dr. Farhad Vahid is a prominent researcher at the Luxembourg Institute of Health, Strassen, specializing in nutritional epidemiology, diet-related cardiometabolic health, and public health interventions. His research focuses on understanding the impact of dietary patterns, inflammatory indices, antioxidants, and nutrient intake on chronic diseases, including cardiovascular risk, obesity, breast cancer, and reproductive health. Dr. Vahid has contributed to advancing population-based and clinical research through large cohort studies, randomized clinical trials, and systematic reviews, providing evidence for the development of diet quality indices and population health guidelines. His work emphasizes the intersection of nutrition, chronic disease prevention, and healthy aging, with translational implications for both individual and public health outcomes. Over his career, he has demonstrated strong collaborative engagement, working with multidisciplinary teams across international institutions to address global health challenges through diet and lifestyle interventions. Dr. Vahid’s publications, including studies on dietary carotenoids, the dietary inflammatory index, cardiovascular risk factors, and healthy aging, have informed both scientific understanding and practical public health strategies. His research not only contributes to academic knowledge but also has significant societal impact by guiding nutritional recommendations and interventions aimed at reducing chronic disease burden and promoting population health. Dr. Vahid’s academic influence and research productivity are reflected in his metrics 1,529 citations, 100 documents, and an h-index of 22.

Profiles: Google Scholar | Scopus | ORCID | ResearchGate | LinkedIn

Featured Publications

Vahid, F., Zand, H., Nosrat–Mirshekarlou, E., Najafi, R., & Hekmatdoost, A. (2015). The role dietary of bioactive compounds on the regulation of histone acetylases and deacetylases: A review. Gene, 562(1), 8–15. Cited by 237.

Vahid, F., Shivappa, N., Hekmatdoost, A., Hebert, J. R., Davoodi, S. H., & Sadeghi, M. (2017). Association between maternal dietary inflammatory index (DII) and abortion in Iranian women and validation of DII with serum concentration of inflammatory factors: Case-control study. Applied Physiology, Nutrition, and Metabolism, 42(5), 511–516. Cited by 110.

Ashkar, F., Rezaei, S., Salahshoornezhad, S., Vahid, F., Gholamalizadeh, M., & [others]. (2020). The role of medicinal herbs in treatment of insulin resistance in patients with polycystic ovary syndrome: A literature review. Biomolecular Concepts, 11(1), 57–75. Cited by 96.

Vahid, F., Shivappa, N., Faghfoori, Z., Khodabakhshi, A., Zayeri, F., & Hebert, J. R. (2018). Validation of a dietary inflammatory index (DII) and association with risk of gastric cancer: A case-control study. Asian Pacific Journal of Cancer Prevention: APJCP, 19(6), 1471. Cited by 92.

Vahid, F., Shivappa, N., Karamati, M., Naeini, A. J., Hebert, J. R., & Davoodi, S. H. (2017). Association between dietary inflammatory index (DII) and risk of prediabetes: A case-control study. Applied Physiology, Nutrition, and Metabolism, 42(4), 399–404. Cited by 85.

Sheeba Irshad | Tumour Immunology | Editorial Board Member

Published on by Oncology

Dr. Sheeba Irshad | Tumour Immunology | Editorial Board Member

Senior Clinical Lecturer | King’s College London | United Kingdom

Dr. Sheeba Irshad is a distinguished clinician-scientist at Guy’s Hospital, London, specializing in translational oncology, tumor immunology, and precision medicine, with a strong focus on breast cancer, immune surveillance, therapeutic resistance, oncolytic viro-immunotherapy, and treatment-related toxicities. Her pioneering work advances immune-based therapeutic innovation through Fc-engineered antibodies, viral vaccine–driven T-cell activation, immunomodulatory gene therapies, and strategies aimed at reversing T-cell exhaustion in poorly immunogenic tumors. She has authored 61 publications in leading journals such as Cancer Research, Molecular Therapy, Translational Oncology, and PLOS ONE, addressing critical challenges including breast cancer cardiotoxicity, radiation-induced fibrosis, and the complex interplay between viral immunity and tumor control. Dr. Irshad’s extensive global collaborations—spanning more than 1,300 co-authors—demonstrate her leadership within multidisciplinary cancer research networks and her commitment to integrating molecular biology, immunology, and clinical oncology to accelerate therapeutic translation. Her contributions have significantly influenced the development of safer and more effective immunotherapies, improving patient outcomes and shaping modern oncology practice worldwide. Dr. Irshad’s academic influence and research productivity are reflected in her metrics 2,293 citations, 61 documents, and an h-index of 22.

Profiles: Scopus| ORCID | LinkedIn

Featured Publications

Cheung, A., Chenoweth, A. M., Johansson, A., Laddach, R., Guppy, N., Trendell, J., Esapa, B., Mavousian, A., Navarro-Llinas, B., Haider, S., et al. (2024). Anti-EGFR antibody-drug conjugate carrying an inhibitor targeting CDK restricts triple-negative breast cancer growth. Clinical Cancer Research.

Hsu, R., Al-Zubeidy, B., Flores, D., Nazarian, A., Baugh, A., Gonzalez, E., Castanon, S., Xiu, J., Kang, I., Spicer, D., et al. (2024). Evaluation of markers of immunity in different metastatic immune microenvironments suggests more suppression within breast-to-liver metastases in breast cancer. Breast Cancer Research and Treatment.

Jahangir, C. A., Page, D. B., Broeckx, G., Gonzalez, C. A., Burke, C., Murphy, C., Reis-Filho, J. S., Ly, A., Harms, P. W., Gupta, R. R., et al. (2024). Image-based multiplex immune profiling of cancer tissues: Translational implications. Report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. The Journal of Pathology.

Tang, C. C., Timbres, J., Ramsey, K., Mera, A., Irshad, S., Sawyer, E., & Khan, A. (2023). Clinico-pathological co-variates define a predictive model of breast cancer-related lymphoedema (BCRL) in patients undergoing axillary surgery for breast cancer. Cancer Research.

Fatayer, H., O’Connell, R. L., Bannon, F., Coles, C. E., Copson, E., Cutress, R. I., Dave, R. V., Gardiner, M. D., Grayson, M., Holcombe, C., et al. (2023). Current practice and surgical outcomes of neoadjuvant chemotherapy for early breast cancer: UK NeST study (Vol. 109, p. 800, 2022). BJS.

Kimihide Kusafuka | Neck Cancer | Editorial Board Member

Published on by Oncology

Dr. Kimihide Kusafuka | Neck Cancer | Editorial Board Member

Clinical Physician | Shizuoka General Hospital | Japan

Dr. Kimihide Kusafuka is a distinguished pathologist at Shizuoka General Hospital, Japan, internationally recognized for his expertise in head and neck pathology, salivary gland tumors, and molecular oncopathology. His research has been instrumental in redefining diagnostic criteria, histopathological classifications, and gene alteration profiles across a spectrum of rare and aggressive neoplasms. Dr. Kusafuka has contributed significantly to the understanding of salivary duct carcinoma, adenoid cystic carcinoma, mucoepidermoid carcinoma, and solitary fibrous tumors through large-cohort analyses, multi-institutional collaborations, and advanced molecular techniques, including MYB/MYBL1 rearrangement characterization, CRTC1/3-MAML2 fusion analysis, and the identification of novel tumor variants. His scholarly output comprises 100 peer-reviewed documents, reflecting a sustained commitment to translational pathology and precision diagnostics. With more than 380 collaborators worldwide, his work has shaped global guidelines, influenced tumor classification systems, and improved prognostic assessment models for clinicians and researchers in the field. Dr. Kusafuka’s studies spanning molecular pathology, surgical pathology, and carcinoma outcome prediction—continue to strengthen diagnostic accuracy and therapeutic decision-making, ultimately improving patient outcomes and contributing to the advancement of cancer pathology. His rigorous methodologies, cross-disciplinary partnerships, and leadership in multi-center Japanese cohorts highlight his role as a leading figure in contemporary oncologic pathology. Dr. Kusafuka’s academic influence and research productivity are reflected in his metrics: 1,768 citations, 100 documents, and an h-index of 25.

Profiles: Scopus| ORCID | ResearchGate

Featured Publications

Kusafuka, K., et al. (2022). A symptomatic intercalated duct lesion of the parotid gland: A case report with immunohistochemical and genetic analyses. Medical Molecular Morphology. Citations: 2

Kusafuka, K., et al. (2022). Salivary gland polymorphous adenocarcinoma: Clinicopathological features and gene alterations in 36 Japanese patients. Journal of Oral Pathology and Medicine.Citations: 6

Kusafuka, K., et al. (2022). Intraoral basal cell carcinoma of the soft palate: A diagnostic pitfall. Citations: 2

Kusafuka, K., et al. (2022). The implicated clinical factors for outcomes in 304 patients with salivary duct carcinoma: Multi-institutional retrospective analysis in Japan. Head & Neck.  Citations: 12

Kusafuka, K., et al. (2022). Salivary mucoepidermoid carcinoma: Histological variants, grading systems, CRTC1/3-MAML2 fusions, and clinicopathological features. Histopathology. Citations: 28

George Kroumpouzos | Skin Oncology | Editorial Board Member

Published on by Oncology

Prof. Dr. George Kroumpouzos | Skin Oncology | Editorial Board Member

Professor | Jundiai Medical School, Brazil / Alpert Medical School of Brown University, USA |  United States

Dr. George Kroumpouzos is an internationally recognized dermatologist affiliated with The Warren Alpert Medical School of Brown University, United States, known for his extensive contributions to medical, surgical, cosmetic, and psychocutaneous dermatology, with a strong recent focus on the integration of artificial intelligence, large language models, and virtual reality into diagnostic and therapeutic practices. He has authored 162 peer-reviewed publications, covering clinically significant topics such as counterfeit botulinum toxin and cosmetic iatrogenic botulism, Er:YAG laser therapy for vulvovaginal atrophy in breast cancer survivors, exosome-based treatments for pattern hair loss, AI-driven innovations in maternal–fetal dermatology, and advanced nonsurgical rhinoplasty techniques. His broad collaborative network spanning more than 200 researchers globally highlights his commitment to interdisciplinary advancement across dermatology, aesthetic medicine, oncology, psychology, and women’s health. Dr. Kroumpouzos’s scholarly work consistently promotes patient safety, diagnostic accuracy, and equitable access to cutting-edge dermatologic care, positioning him as a leading voice in regulatory reform and digital transformation within the field. His global impact is underscored by his ability to bridge clinical insight with emerging technologies, shaping future standards and addressing diverse patient needs across populations. Dr. Kroumpouzos’s academic influence and research productivity are reflected in his metrics: 2,695 citations, 162 documents, and an h-index of 28.

profiles: Scopus| ORCID | ResearchGate

Featured Publications

Türk, C. B., Mirza, F. N., & Kroumpouzos, G. (2023). A screening proposal for Zoom dysmorphia in virtual settings. Life, 13(8), Article 1678.

Bhargava, S., Yumeen, S., Henebeng, E., & Kroumpouzos, G. (2022). Erosive pustular dermatosis: Delving into etiopathogenesis and management. Life, 12(12), Article 2097.

Kroumpouzos, G., Paroikaki, M. E., Yumeen, S., Bhargava, S., & Mylonakis, E. (2022). Cutaneous complications of mRNA and AZD1222 COVID-19 vaccines: A worldwide review. Microorganisms, 10(3), Article 624.

Das, K., Daveluy, S., Kroumpouzos, G., Agarwal, K., Podder, I., Farnbach, K., Ortega-Loayza, A. G., Szepietowski, J. C., Grabbe, S., & Goldust, M. (2022). Efficacy and toxicity of classical immunosuppressants, retinoids and biologics in hidradenitis suppurativa. Journal of Clinical Medicine, 11(3), Article 670.

Messas, T., Messas, A., & Kroumpouzos, G. (2021). Carbon dioxide laser vulvovaginal rejuvenation: A systematic review. Cosmetics, 8(3), Article 56.

Xin Yi Foong | Breast Cancer | Best Researcher Award

Published on by Oncology

Ms. Xin Yi Foong | Breast Cancer | Best Researcher Award

Core Surgical Trainee | Mid Yorkshire Teaching NHS Trust | United Kingdom

Dr Xin Yi Foong is a clinical researcher in Plastic and Reconstructive Surgery whose academic work is centred on improving the safety, accuracy, and reliability of autologous breast reconstruction through quantitative imaging and evidence-based microsurgical innovation. Her research explores the use of indocyanine green (ICG) fluorescence imaging to guide intraoperative evaluation of mastectomy flap perfusion, with particular emphasis on establishing objective perfusion scoring methods that support consistent, data-guided surgical decisions. Her published study in the Journal of Plastic, Reconstructive & Aesthetic Surgery introduced a structured quantitative perfusion algorithm that demonstrated strong discriminatory capability in identifying poorly perfused tissue and informing reconstructive planning, offering evidence that aligns with national quality frameworks and enhances postoperative outcomes. Alongside this work, she is investigating postoperative monitoring strategies in DIEP flap reconstruction, assessing early-phase observation models that preserve patient safety while promoting efficient and clinically coherent perioperative pathways. Her wider academic activity includes outcome audits, service-improvement initiatives, and reconstructive pathway analyses, all aimed at refining surgical workflows through quantitative measures, imaging-based assessment, and rigorous postoperative metrics. Conducted within multidisciplinary teams of plastic surgeons, anaesthetists, and breast specialists, her research supports the translation of imaging-derived insights into routine clinical practice. Through a growing publication profile, an active ORCID research identity, and sustained commitment to scientifically grounded surgical advancement, Dr Foong contributes to the development of reproducible, clinically meaningful, and patient-centred innovations that strengthen microsurgical dependability and elevate the overall quality of care within reconstructive breast surgery.

Profiles: Scopus | ORCID

Featured Publications

1. Foong, X. Y., Williamson, A., Lymperopoulos, N., & Holmes, W. J. M. (2025). Does indocyanine green imaging perfusion scoring reduce mastectomy flap necrosis in immediate autologous breast reconstruction? A single-centre cohort study. Journal of Plastic, Reconstructive & Aesthetic Surgery, 111, 198–206.

2. Foong, X. Y., Williamson, A., Lymperopoulos, N., & Holmes, W. J. M. (2025). Does intraoperative indocyanine green (ICG) reduce the outcome of mastectomy skin flap necrosis in patients undergoing immediate breast reconstruction? European Journal of Surgical Oncology. Advance online publication. 

Gerardo Rosati | Breast Cancer | Best Researcher Award

Published on by Oncology

Dr. Gerardo Rosati | Breast Cancer | Best Researcher Award

Azienda Ospedaliera San Carlo di Potenza | Italy

Dr. Gerardo Rosati is a distinguished Italian medical oncologist whose career reflects over three decades of sustained clinical practice, research leadership, and commitment to advancing evidence-based cancer care. Laureato con lode all’Università “Federico II” di Napoli e successivamente specializzato in Oncologia presso la Seconda Università di Napoli, ha sviluppato precocemente un interesse scientifico per i markers tumorali e per l’innovazione terapeutica nei tumori solidi. La sua formazione è stata arricchita da numerose borse di studio FIRC, ESO e Fondazione Lina Belli, che gli hanno consentito di partecipare a corsi avanzati internazionali su colon-retto, neuro-oncologia, recidive ginecologiche, terapia antalgica e strategie emergenti in oncologia medica. Dal 1998 opera stabilmente presso l’U.O. di Oncologia Medica dell’Azienda Ospedaliera “S. Carlo” di Potenza, dove ha assunto ruoli via via più qualificati fino alla responsabilità del coordinamento dell’attività di ricerca clinica. La sua attività come sperimentatore in oltre cento studi clinici di fase I–III e in numerosi progetti osservazionali riguarda chemioterapie innovative, farmaci biologici, anti-EGFR, anti-angiogenici, immunoterapia, tossicità correlate ai trattamenti e biomarcatori predittivi. Ha inoltre svolto un’intensa attività di revisione scientifica per riviste internazionali e per enti accademici e sanitari nazionali, contribuendo al miglioramento della qualità metodologica della ricerca oncologica. Membro attivo di AIOM, ESMO ed ESO College, promuove l’integrazione tra clinica, ricerca e formazione, con un impatto significativo sui percorsi assistenziali nei tumori gastrointestinali e in altre neoplasie solide. His academic influence is reflected in 2,813 citations, 123 documents, and an h-index of 27, underscoring his meaningful contributions to contemporary clinical oncology.

Profiles: Scopus | ORCID

Featured Publications

1. Rosati, G., De Stefano, A., Restivo, A., Fanotto, V., Cicero, G., Colombo, A., Dell’Aquila, E., Parisi, A., Ortolani, S., Lutrino, S. E., Carlomagno, C., Dapoto, F., Reggiardo, G., Tonetto, F., Ravo, V., Aprile, G., Bilancia, D., Avallone, A., Romano, C., Argiolas, V., & Giovinazzo, G. (2026). Short-Course Radiotherapy for Older Patients with Locally Advanced Rectal Cancer and Unfit for Chemotherapy: The SOFT Study. Radiotherapy and Oncology.

2. Rosati, G., Piccirillo, M. C., Nasti, G., De Stefano, A., Carlomagno, C., Romano, C., Cassata, A., Silvestro, L., Nappi, A., Perrone, F., Budillon, A., & Avallone, A. (2025). A Post Hoc Analysis of Older Patients with Metastatic Colorectal Cancer Receiving Oxaliplatin-Based Chemotherapy Plus Bevacizumab: The Randomized Obelics Study. Drugs & Aging, 1–10.

3. Avallone, A., Giuliani, F., De Stefano, A., Santabarbara, G., Nasti, G., Montesarchio, V., Rosati, G., Cassata, A., Leo, S., Romano, C., Tamburini, E., Silvestro, L., Lotesoriere, C., Nappi, A., Santini, D., Petrillo, A., Colombo, A., Febbraro, A., Leone, A., Mannavola, F., & Laterza, M. M. (2024). Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The IMPROVE Trial. Journal of Clinical Oncology, 43(7), 829–839.

4. Montrone, M., Rosati, G., Longo, V., Catino, A., Massafra, R., Nardone, A., Pesola, F., Montagna, E. S., Marech, I., & Pizzutilo, P. (2023). Immunotherapy in Elderly Patients Affected by Non-Small Cell Lung Cancer: A Narrative Review. Journal of Clinical Medicine, 12(5), 1833.

5. Rosati, G., Montrone, M., Pacilio, C., Colombo, A., Cicero, G., Paragliola, F., Vaia, A., Annunziata, L., & Bilancia, D. (2022). An Update on the Role of Anti-EGFR in the Treatment of Older Patients with Metastatic Colorectal Cancer. Journal of Clinical Medicine, 11(23), 7108.

Aminah Alotaibi | Breast Cancer | Best Researcher Award

Published on by Oncology

Dr. Aminah Alotaibi | Breast Cancer | Best Researcher Award

Assistant Research Professor | King Abdulaziz city for science and technology | Saudi Arabia

Dr. Aminah Ghazi Alotaibi is a distinguished researcher affiliated with the King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia. With a Scopus h-index of 3, 4 indexed publications, and 58 citations, she has demonstrated consistent scholarly impact in the fields of hematology, stem cell biology, and molecular diagnostics. Her research primarily focuses on elucidating the phenotypic and molecular diversity of hematopoietic stem and progenitor cells (HSPCs) derived from cord blood and bone marrow, advancing the understanding of their biological significance and translational potential in clinical applications. Notably, her recent open-access article titled “Distinct Phenotypic and Molecular Characteristics of CD34− and CD34+ Hematopoietic Stem/Progenitor Cell Subsets in Cord Blood and Bone Marrow Samples: Implications for Clinical Applications” (2025, Diagnostics) highlights her expertise in cellular characterization and regenerative medicine, offering valuable insights for stem cell-based therapies and transplantation science. Dr. Alotaibi’s collaborative network spans 23 co-authors, reflecting her active engagement in multidisciplinary and international scientific research. Her work integrates clinical hematology, genomics, and translational biomedical research, bridging the gap between laboratory discoveries and patient-centered innovations. Through her contributions, she aims to enhance diagnostic precision, therapeutic efficacy, and personalized medical approaches in hematologic and immune-related disorders. Dr. Alotaibi’s scholarly endeavors not only strengthen Saudi Arabia’s presence in global biomedical research but also contribute to the broader scientific community’s understanding of stem cell biology and its clinical potential.

Profiles: Google Scholar | Scopus | ORCID | LinkedIn

Featured Publications

1. Alotaibi, A. G., Li, J. V., & Gooderham, N. J. (2021). Tumour necrosis factor-α (TNF-α) enhances dietary carcinogen-induced DNA damage in colorectal cancer epithelial cells through activation of JNK signaling pathway. Toxicology, 457, 152806. Cited by: 36

2. Al-Saleh, I., Elkhatib, R., Al-Rajoudi, T., Al-Qudaihi, G., Manogarannogaran, P., Alotaibi, A. G., & others. (2020). Cytotoxic and genotoxic effects of e-liquids and their potential associations with nicotine, menthol and phthalate esters. Chemosphere, 249, 126153. Cited by: 22

3. Alotaibi, A. G., Li, J. V., & Gooderham, N. J. (2023). Tumour necrosis factor-alpha (TNF-α)-induced metastatic phenotype in colorectal cancer epithelial cells: Mechanistic support for the role of microRNA-21. Cancers, 15(3), 627. Cited by: 21

4. Gaafar, A., Hamza, F. N., Yousif, R., Shinwari, Z., Alotaibi, A. G., Iqniebi, A., & others. (2025). Distinct phenotypic and molecular characteristics of CD34− and CD34+ hematopoietic stem/progenitor cell subsets in cord blood and bone marrow samples: Implications for clinical applications. Diagnostics, 15(4), 447. Cited by: 1

5. Alotaibi, A. G. (2023). Effect of the inflammatory mediator TNF-α on colorectal cancer epithelial cells development and metastasis, role of dietary carcinogens and miRNA [Doctoral dissertation, Imperial College London]. Imperial College Repository.

Dr. Aminah Ghazi Alotaibi’s research advances global understanding of inflammation-driven carcinogenesis and stem cell biology, bridging molecular insights with clinical translation. Her work contributes to precision oncology, regenerative medicine, and the development of safer therapeutic strategies, fostering innovation that benefits both scientific progress and human health worldwide.

Mirjana Popadić | Carcinoma | Best Researcher Award

Published on by Oncology

Dr. Mirjana Popadić | Carcinoma | Best Researcher Award

Dermatovenerologist-Oncologist | Medigroup | Serbia

Dr. Mirjana Popadić is a distinguished researcher and faculty member at the University of Belgrade, Serbia, with a strong academic and clinical focus on dermatology, particularly in the diagnostic and histopathological evaluation of skin lesions. Over the course of her career, she has contributed significantly to the advancement of dermatological science, with 15 published research documents and over 121 citations, reflecting her growing influence within the global dermatology research community. Her work bridges the gap between clinical practice and experimental dermatopathology, with a special emphasis on innovative diagnostic techniques such as vertical ex vivo dermoscopy, a promising approach for improving the accuracy and differentiation of cutaneous lesions. Dr. Popadić’s research output, characterized by methodological precision and translational value, underscores her commitment to enhancing diagnostic reliability and patient outcomes in dermatologic oncology and inflammatory skin diseases. With an h-index of 7, her studies have been cited and utilized by peers across multiple institutions, demonstrating her active engagement in international scholarly collaboration. She has co-authored with nine other researchers, reflecting her interdisciplinary approach and contribution to collective scientific advancement. As a representative of the University of Belgrade, Dr. Popadić’s work not only reinforces Serbia’s academic presence in global dermatological research but also provides essential insights into the development of evidence-based diagnostic methodologies. Her scholarly contributions, teaching involvement, and clinical expertise together form a robust academic profile dedicated to the pursuit of excellence in skin pathology research, medical education, and healthcare innovation.

Profiles: Scopus | ORCID | ResearchGate | LinkedIn

Featured Publications

1. Popadić, M., Brasanac, D., Milošev, D., Ravić Nikolić, A., & Mitrović, S. (2024). Vertical ex vivo dermoscopy in assessment of malignant skin lesions. Biomedicines, 12(8), 1683.

2. Popadić, M. (2018). Dermatoscopy of multiple piloleiomyomas with disseminated and segmental distribution. Indian Journal of Dermatology, Venereology and Leprology.

3. Popadić, M. (2018). Cutaneous polyarteritis nodosa: Uncommon and rare form of cutaneous vasculitis. Serbian Journal of Dermatology and Venereology, 10(2), 65–70.

4. Popadić, M. (2017). The significance of blue color in dermatoscopy. Journal der Deutschen Dermatologischen Gesellschaft (JDDG).

5. Popadić, M. (2016). Dermatoscopy in diagnosing maculopapular cutaneous mastocytosis. Praxis Medica.

Dr. Mirjana Popadić’s research advances the precision and reliability of dermatological diagnostics through innovative dermoscopic and histopathological techniques. Her contributions enhance early detection of malignant and rare skin disorders, bridging clinical practice and research to improve patient outcomes and promote global standards in dermatologic oncology.

Omar Alqaisi | Skin Cancer | Best Researcher Award

Published on by Oncology

Mr. Omar Alqaisi | Skin Cancer | Best Researcher Award

Al-Zaytoonah University of Jordan | Jordan

Dr. Omar M. Alqaisi is a dedicated academic and researcher at Al-Zaytoonah University of Jordan whose scholarly contributions reflect a strong commitment to advancing healthcare through evidence-based nursing practice and oncology research. With 11 published documents, 46 citations, and an h-index of 3, his work demonstrates a consistent trajectory of academic growth and increasing impact in the fields of clinical nursing, psycho-oncology, and patient-centered care. His notable publication, “A Narrative Review of the Roles of Nursing in Addressing Sexual Dysfunction in Oncology Patients,” underscores his focus on addressing sensitive and underexplored areas of oncology, particularly the psychosocial and emotional well-being of cancer patients, while emphasizing the indispensable role of nurses in holistic recovery and improving quality of life. A hallmark of his career is his emphasis on interdisciplinary collaboration, evidenced by co-authorship with more than 100 researchers across multiple disciplines, reflecting his ability to foster teamwork and integrate diverse perspectives to address complex healthcare challenges. His research is characterized by analytical precision, ethical grounding, and a human-centered approach, aligning with global healthcare trends that prioritize compassion, inclusivity, and evidence-based interventions. Beyond individual studies, Dr. Alqaisi’s work contributes to the broader advancement of nursing education, clinical practice, and patient advocacy in oncology. His growing academic influence positions him as an emerging leader within regional and international research communities. With continued development in empirical methodologies, digital health innovations, and cross-cultural healthcare models, he is poised to expand his contributions to global nursing and oncology discourse. Dr. Alqaisi’s research not only advances academic understanding but also creates meaningful societal impact by emphasizing empathy, communication, and the integration of psychosocial care into clinical frameworks, exemplifying a new generation of scholars committed to bridging scientific innovation with humanistic healthcare practice.

Profiles: Scopus | ORCID | ResearchGate

Featured Publications

1. Tai, P., Alqaisi, O., Al-Ghabeesh, S., Sijarina, L., Yu, E., Thachuthara, A. J., Assouline, A., Souied, O., Hagel, K., & Joseph, K. (2025, October 9). Immune checkpoint inhibitors in Merkel cell carcinoma of the skin: A 2025 comprehensive review. Cancers, 17(19), 3272.

2. Alqaisi, O., Al-Ghabeesh, S., Tai, P., Wong, K., Joseph, K., & Yu, E. (2025, August 14). A narrative review of the roles of nursing in addressing sexual dysfunction in oncology patients. Current Oncology, 32(8), 457.

3. Tai, P., Alqaisi, O., Al-Ghabeesh, S., Sijarina, L., Yu, E., Thachuthara, A. J., Assouline, A., Souied, O., Hagel, K., & Joseph, K. (2025, July 25). Immunotherapy in Merkel cell carcinoma of the skin: A 2025 comprehensive review. Preprints, 202507.2063.v1.

4. Alqaisi, O., Subih, M., Joseph, K., Yu, E., & Tai, P. (2025, June). Oncology nurses’ attitudes, knowledge, and practices in providing sexuality care to cancer patients: A scoping review. Current Oncology, 32(6), 337.

5. Alqaisi, O. M., & Al-Ghabeesh, S. (2024, July 31). Quality of postoperative pain management in orthopedic patients and its impact on sleep quality and patient satisfaction: An integrative review. Cureus, 16(7), e65872.

Dr. Omar M. Alqaisi’s research advances the integration of compassionate, evidence-based nursing within oncology care, addressing both clinical and psychosocial patient needs. His work strengthens global healthcare practices by promoting interdisciplinary collaboration, enhancing patient quality of life, and shaping innovative models for holistic, human-centered medical care.